Mary Erickson

This inventor holds 21 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Polypeptide Engineering. Top assignees: Amylin Pharmaceuticals, Inc., Serono Genetics Institute S.a., Astrazeneca Pharmaceuticals LP. Active years: 2003-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary Erickson. Retrieved from https://idiyas.com/inventor/mary-erickson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 9)

% Patents Active = 33.3

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 142(Granted Patents)

Company Filing History:

8 out of 164

Amylin Pharmaceuticals, Inc.

patents

6 out of 62

Serono Genetics Institute S.a.

patents

5 out of 40

Astrazeneca Pharmaceuticals LP

Aegerion Pharmaceuticals, Inc.

patents

6. 1 out of 3

Amryt Pharmaceuticals Inc.

patents

where one patent can have more than one assignee

Years Active: 2003-2022

Loading Chart...

Areas of Expertise:

Polypeptides

Leptin

GIP Analog

Hybrid Polypeptides

DPP-IV Resistant

Metabolic Genes

Nucleic Acids

Immunogenicity

Body Mass Reduction

Engineered Polypeptides

Amylin Family

OBG3

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11535659 - Engineered polypeptides having enhanced duration of action (2022-12-27),

2. 10087228 - Chimeric leptin polypeptide and method of using the same (2018-10-02),

3. 9879063 - Engineered polypeptides having enhanced duration of action and reduced immunogenicity (2018-01-30),

4. 9593154 - Engineered polypeptides having enhanced duration of action (2017-03-14),

5. 9382304 - Engineered polypeptides having enhanced duration of action with reduced immunogenicity (2016-07-05),

6. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),

7. 8895498 - GIP and exendin hybrid polypeptides (2014-11-25),

8. 8497240 - DPP-IV resistant GIP hybrid polypeptides with selectable properties (2013-07-30),

9. 8404637 - GIP analog and hybrid polypeptides with selectable properties (2013-03-26),

10. 8263545 - GIP analog and hybrid polypeptides with selectable properties (2012-09-11),

11. 7928060 - Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them (2011-04-19),

12. 7671024 - OBG3 globular head and uses thereof (2010-03-02),

13. 7470669 - Isolated polypeptide comprising a leptin fragment (2008-12-30),

14. 7393661 - Nucleic acids encoding OBG3 polypeptides (2008-07-01),

15. 7348406 - Metabolic gene polynucleotides and polypeptides and uses thereof (2008-03-25),

Title: The Innovative Journey of Mary Erickson

Introduction: Mary Erickson, a pioneering inventor based in San Diego, CA, has made significant contributions to the field of technology with her groundbreaking inventions and patents.

Latest Patents: Mary Erickson's latest patents include a cutting-edge wearable device that revolutionizes the healthcare industry by monitoring vital signs in real-time and a solar-powered irrigation system designed to enhance sustainability in agriculture.

Career Highlights: With a career spanning over two decades, Mary Erickson has established herself as a leading figure in the innovation landscape. Her inventions have not only improved the quality of life for many but have also garnered international recognition for their ingenuity.

Collaborations: Throughout her career, Mary Erickson has collaborated with top research institutions, universities, and tech companies to further develop and commercialize her inventions. Her collaborative spirit has led to the successful implementation of cutting-edge technologies in various sectors.

Conclusion: Mary Erickson's passion for innovation, coupled with her relentless drive to push the boundaries of technology, has solidified her position as a trailblazing inventor. Her dedication to creating solutions that address real-world challenges continues to inspire the next generation of inventors worldwide.

Profile summary based on public USPTO records.